Jubilant Ingrevia Limited — Board Meeting, 26-05-2026: Outcome of Board Meeting

Jubilant Ingrevia's board approved Q4 & FY26 financial results. A final dividend of ₹2.5/share was declared, bringing the total FY26 dividend to ₹5/share (₹79.64 Cr). Strategic move: Remidex Pharma acquired for ₹16.28 Cr to boost nutrition/pharma. A ₹13.04 Cr one-time labor code expense was also recorded.